Form 4: AVITA Medical Director Jan Stern Reed Reports Equity Compensation Grant

AVITA Medical, Inc. Director Jan Stern Reed has reported the acquisition of 10,022 restricted stock units and 4,295 stock options as part of her compensation, following stockholder approval.

Summary

• Jan Stern Reed, a Director at AVITA Medical, Inc. (RCEL), reported the acquisition of equity securities.
• On January 21, 2025, Ms. Reed was granted 10,022 restricted stock units (RSUs), each representing a contingent right to one share of Common Stock.
• These RSUs are subject to time-based vesting criteria and will vest on January 21, 2026, which is 12 months following the grant date.
• The total amount of Common Stock beneficially owned by Ms. Reed following this transaction is 51,011 shares, which includes these unvested RSUs.
• Additionally, on January 21, 2025, Ms. Reed was granted 4,295 stock options to acquire 4,295 shares of Common Stock.
• The exercise price for these stock options is $8.73 per share, which was the closing price of AVITA Medical's Common Stock on Nasdaq on the grant date.
• These stock options become exercisable on January 21, 2026, and have an expiration date of January 21, 2035.
• Both the RSU and stock option grants were subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

Sentiment

Score: 5

Explanation: The document reports a standard equity compensation grant to a director, which is a neutral event in terms of immediate company performance or outlook. It reflects routine corporate compensation practices.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The stockholder approval of these equity awards demonstrates good corporate governance and transparency regarding director compensation.

Future Outlook

The document indicates future vesting of restricted stock units and exercisability of stock options, aligning director incentives with long-term company performance.

Industry Context

This filing represents a routine compensation event for a director within the medical device or biotechnology industry, where equity-based compensation is a common practice to attract and retain talent and align interests with shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for director compensation is a standard practice across many industries, including healthcare and biotechnology, aligning with common corporate governance benchmarks.
• The requirement for stockholder approval for these equity grants is a strong corporate governance practice, often seen in well-governed companies, ensuring transparency and accountability in executive and director compensation.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to Jan Stern Reed, a director of AVITA Medical, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value creation, as the value of the awards is tied to the company's stock performance.
• Employees: While not directly impacting employees, such compensation practices can set precedents for broader company compensation strategies.

Next Steps

• The restricted stock units are scheduled to vest on January 21, 2026.
• The stock options will become exercisable on January 21, 2026, and expire on January 21, 2035.

Key Dates

Keywords

AVITA Medical, RCEL, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Corporate Governance